Nitric oxide synthase 3 (eNOS) (eNOS)

Nitric oxide synthase 3 (eNOS) is a constitutive, calcium-calmodulin-dependent enzyme primarily localized to the vascular endothelium, where it plays a fundamental role in maintaining cardiovascular homeostasis (UniProt: P29474). It catalyzes the synthesis of nitric oxide (NO) from the amino acid L-arginine, a process that requires several cofactors including oxygen, NADPH, and tetrahydrobiopterin (BH4) (StatPearls: Physiology, Nitric Oxide). The NO produced by eNOS diffuses into adjacent vascular smooth muscle cells, activating soluble guanylyl cyclase to produce cGMP, which triggers vasodilation and regulates blood pressure (PubMed: PMID 25031023). Beyond its role as a vasodilator, eNOS-derived NO exerts anti-atherogenic effects by inhibiting platelet aggregation, reducing leukocyte adhesion to the vessel wall, and suppressing smooth muscle cell proliferation (PubChem: NOS3). Dysfunction of this pathway, often termed endothelial dysfunction, is a precursor to major cardiovascular diseases such as hypertension, atherosclerosis, and diabetes-related vascular complications. Therapeutic interventions often target this pathway indirectly; for instance, statins and certain beta-blockers like nebivolol enhance eNOS expression and activity to restore vascular health and improve blood flow.

Other names

Endothelial nitric oxide synthaseNOS3Constitutive NOSEC-NOSNOS III

Pharmacological agents modulate this pathway by enhancing the phosphorylation and activation of the eNOS enzyme, increasing its gene expression, or providing essential cofactors like tetrahydrobiopterin (BH4) to prevent enzymatic uncoupling.